Aurora kinase A in gastrointestinal cancers

Time to target

Ahmed Katsha, Abbes Belkhiri, Laura Goff, Wael El-Rifai

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Gastrointestinal (GI) cancers are a major cause of cancer-related deaths. During the last two decades, several studies have shown amplification and overexpression of Aurora kinase A (AURKA) in several GI malignancies. These studies demonstrated that AURKA not only plays a role in regulating cell cycle and mitosis, but also regulates a number of key oncogenic signaling pathways. Although AURKA inhibitors have moved to phase III clinical trials in lymphomas, there has been slower progress in GI cancers and solid tumors. Ongoing clinical trials testing AURKA inhibitors as a single agent or in combination with conventional chemotherapies are expected to provide important clinical information for targeting AURKA in GI cancers. It is, therefore, imperative to consider investigations of molecular determinants of response and resistance to this class of inhibitors. This will improve evaluation of the efficacy of these drugs and establish biomarker based strategies for enrollment into clinical trials, which hold the future direction for personalized cancer therapy. In this review, we will discuss the available data on AURKA in GI cancers. We will also summarize the major AURKA inhibitors that have been developed and tested in pre-clinical and clinical settings.

Original languageEnglish (US)
Article number106
JournalMolecular Cancer
Volume14
Issue number1
DOIs
StatePublished - May 20 2015
Externally publishedYes

Fingerprint

Aurora Kinase A
Gastrointestinal Neoplasms
Neoplasms
Clinical Trials
Phase III Clinical Trials
Drug Evaluation
Mitosis
Lymphoma
Cell Cycle
Biomarkers
Drug Therapy

Keywords

  • Alisertib
  • AURKA inhibitors
  • Aurora kinases
  • Cancer
  • Gastrointestinal
  • MNL8237
  • Signaling pathways
  • Therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

Aurora kinase A in gastrointestinal cancers : Time to target. / Katsha, Ahmed; Belkhiri, Abbes; Goff, Laura; El-Rifai, Wael.

In: Molecular Cancer, Vol. 14, No. 1, 106, 20.05.2015.

Research output: Contribution to journalReview article

Katsha, Ahmed ; Belkhiri, Abbes ; Goff, Laura ; El-Rifai, Wael. / Aurora kinase A in gastrointestinal cancers : Time to target. In: Molecular Cancer. 2015 ; Vol. 14, No. 1.
@article{6a1835a6bc414a80a864e3bb1dadfbdb,
title = "Aurora kinase A in gastrointestinal cancers: Time to target",
abstract = "Gastrointestinal (GI) cancers are a major cause of cancer-related deaths. During the last two decades, several studies have shown amplification and overexpression of Aurora kinase A (AURKA) in several GI malignancies. These studies demonstrated that AURKA not only plays a role in regulating cell cycle and mitosis, but also regulates a number of key oncogenic signaling pathways. Although AURKA inhibitors have moved to phase III clinical trials in lymphomas, there has been slower progress in GI cancers and solid tumors. Ongoing clinical trials testing AURKA inhibitors as a single agent or in combination with conventional chemotherapies are expected to provide important clinical information for targeting AURKA in GI cancers. It is, therefore, imperative to consider investigations of molecular determinants of response and resistance to this class of inhibitors. This will improve evaluation of the efficacy of these drugs and establish biomarker based strategies for enrollment into clinical trials, which hold the future direction for personalized cancer therapy. In this review, we will discuss the available data on AURKA in GI cancers. We will also summarize the major AURKA inhibitors that have been developed and tested in pre-clinical and clinical settings.",
keywords = "Alisertib, AURKA inhibitors, Aurora kinases, Cancer, Gastrointestinal, MNL8237, Signaling pathways, Therapy",
author = "Ahmed Katsha and Abbes Belkhiri and Laura Goff and Wael El-Rifai",
year = "2015",
month = "5",
day = "20",
doi = "10.1186/s12943-015-0375-4",
language = "English (US)",
volume = "14",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Aurora kinase A in gastrointestinal cancers

T2 - Time to target

AU - Katsha, Ahmed

AU - Belkhiri, Abbes

AU - Goff, Laura

AU - El-Rifai, Wael

PY - 2015/5/20

Y1 - 2015/5/20

N2 - Gastrointestinal (GI) cancers are a major cause of cancer-related deaths. During the last two decades, several studies have shown amplification and overexpression of Aurora kinase A (AURKA) in several GI malignancies. These studies demonstrated that AURKA not only plays a role in regulating cell cycle and mitosis, but also regulates a number of key oncogenic signaling pathways. Although AURKA inhibitors have moved to phase III clinical trials in lymphomas, there has been slower progress in GI cancers and solid tumors. Ongoing clinical trials testing AURKA inhibitors as a single agent or in combination with conventional chemotherapies are expected to provide important clinical information for targeting AURKA in GI cancers. It is, therefore, imperative to consider investigations of molecular determinants of response and resistance to this class of inhibitors. This will improve evaluation of the efficacy of these drugs and establish biomarker based strategies for enrollment into clinical trials, which hold the future direction for personalized cancer therapy. In this review, we will discuss the available data on AURKA in GI cancers. We will also summarize the major AURKA inhibitors that have been developed and tested in pre-clinical and clinical settings.

AB - Gastrointestinal (GI) cancers are a major cause of cancer-related deaths. During the last two decades, several studies have shown amplification and overexpression of Aurora kinase A (AURKA) in several GI malignancies. These studies demonstrated that AURKA not only plays a role in regulating cell cycle and mitosis, but also regulates a number of key oncogenic signaling pathways. Although AURKA inhibitors have moved to phase III clinical trials in lymphomas, there has been slower progress in GI cancers and solid tumors. Ongoing clinical trials testing AURKA inhibitors as a single agent or in combination with conventional chemotherapies are expected to provide important clinical information for targeting AURKA in GI cancers. It is, therefore, imperative to consider investigations of molecular determinants of response and resistance to this class of inhibitors. This will improve evaluation of the efficacy of these drugs and establish biomarker based strategies for enrollment into clinical trials, which hold the future direction for personalized cancer therapy. In this review, we will discuss the available data on AURKA in GI cancers. We will also summarize the major AURKA inhibitors that have been developed and tested in pre-clinical and clinical settings.

KW - Alisertib

KW - AURKA inhibitors

KW - Aurora kinases

KW - Cancer

KW - Gastrointestinal

KW - MNL8237

KW - Signaling pathways

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84929429616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929429616&partnerID=8YFLogxK

U2 - 10.1186/s12943-015-0375-4

DO - 10.1186/s12943-015-0375-4

M3 - Review article

VL - 14

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 106

ER -